Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. (1/279)
Previous studies have demonstrated an important role for the cytochrome P450 (CYT-P450) pathway in afferent arteriole autoregulatory responses but the involvement of specific pathways remains unknown. Experiments were performed to determine the role of CYT-P450 epoxygenase and hydroxylase pathways in pressure mediated preglomerular autoregulatory responses. Afferent arteriolar diameter was measured as renal perfusion pressure was increased from 80-160 mmHg. Afferent arteriolar diameter averaged 19+/-2 microm at a renal perfusion pressure of 80 mmHg and decreased by 15+/-2% when pressure was increased to 160 mmHg. Inhibition of the epoxygenase pathway with 6-(2-proparglyloxyphenyl)hexanoic acid (PPOH), enhanced the microvascular response to increasing renal perfusion pressure. In the presence of 50 microM PPOH, afferent arteriolar diameter decreased by 29+/-4% when pressure was increased from 80-160 mmHg. Likewise, the sulphonimide derivative of PPOH, N-methylsulphonyl-6-(2-proparglyloxyphenyl) hexanamide (MS-PPOH, 50 microM), enhanced the afferent arteriolar response to increasing renal perfusion pressure. In contrast, the selective CYT-P450 hydroxylase inhibitor, N-methylsulphonyl-12,12-dibromododec-11-enamide (DDMS) attenuated the vascular response to increasing renal perfusion pressure. In the pressure of 25 microM DDMS, afferent arteriolar diameter decreased by 4+/-2% when pressure was increased from 80-160 mmHg. These results suggest that CYT-P450 metabolites of the epoxygenase pathway alter afferent arteriolar responsiveness and thereby modify the ability of the preglomerular vasculature to autoregulate renal blood flow. Additionally, these results provide further support to the concept that a metabolite of the hydroxylase pathway is an integral component of the afferent arteriolar response to elevations in perfusion pressure. (+info)Novel biodegradable aromatic plastics from a bacterial source. Genetic and biochemical studies on a route of the phenylacetyl-coa catabolon. (2/279)
Novel biodegradable bacterial plastics, made up of units of 3-hydroxy-n-phenylalkanoic acids, are accumulated intracellularly by Pseudomonas putida U due to the existence in this bacterium of (i) an acyl-CoA synthetase (encoded by the fadD gene) that activates the aryl-precursors; (ii) a beta-oxidation pathway that affords 3-OH-aryl-CoAs, and (iii) a polymerization-depolymerization system (encoded in the pha locus) integrated by two polymerases (PhaC1 and PhaC2) and a depolymerase (PhaZ). The complete assimilation of these compounds requires two additional routes that specifically catabolize the phenylacetyl-CoA or the benzoyl-CoA generated from these polyesters through beta-oxidation. Genetic studies have allowed the cloning, sequencing, and disruption of the genes included in the pha locus (phaC1, phaC2, and phaZ) as well as those related to the biosynthesis of precursors (fadD) or to the catabolism of their derivatives (acuA, fadA, and paa genes). Additional experiments showed that the blockade of either fadD or phaC1 hindered the synthesis and accumulation of plastic polymers. Disruption of phaC2 reduced the quantity of stored polymers by two-thirds. The blockade of phaZ hampered the mobilization of the polymer and decreased its production. Mutations in the paa genes, encoding the phenylacetic acid catabolic enzymes, did not affect the synthesis or catabolism of polymers containing either 3-hydroxyaliphatic acids or 3-hydroxy-n-phenylalkanoic acids with an odd number of carbon atoms as monomers, whereas the production of polyesters containing units of 3-hydroxy-n-phenylalkanoic acids with an even number of carbon atoms was greatly reduced in these bacteria. Yield-improving studies revealed that mutants defective in the glyoxylic acid cycle (isocitrate lyase(-)) or in the beta-oxidation pathway (fadA), stored a higher amount of plastic polymers (1.4- and 2-fold, respectively), suggesting that genetic manipulation of these pathways could be useful for isolating overproducer strains. The analysis of the organization and function of the pha locus and its relationship with the core of the phenylacetyl-CoA catabolon is reported and discussed. (+info)Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. (3/279)
Although the cyclooxygenase pathway of the arachidonic acid cascade has been suggested to play an important role in colon carcinogenesis, the molecular species of prostanoids and receptors involved have not been fully elucidated yet. We examined the development of aberrant crypt foci (ACFs), putative preneoplastic lesions of the colon, in two lines of knockout mice, each deficient in prostaglandin E receptors, EP1 and EP3, by treatment with the colon carcinogen, azoxymethane. Formation of ACFs was decreased only in the EP1-knockout mice to approximately 60% of the level in wild-type mice. Administration of 250, 500, or 1000 ppm of a novel selective EP1 antagonist, ONO-8711, in the diet to azoxymethane-treated C57BL/6J mice also resulted in a dose-dependent reduction of ACF formation. Moreover, when Min mice, having a nonsense mutation in the adenomatous polyposis coli gene, were given 500 ppm ONO-8711 in the diet, the number of intestinal polyps was significantly reduced to 57% of that in the basal diet group. These results strongly suggest that prostaglandin E2 contributes to colon carcinogenesis to some extent through its action at the EP1 receptor. Thus, EP1 antagonists may be good candidates as chemopreventive agents for colon cancer. (+info)Product of side-chain cleavage of cholesterol, isocaproaldehyde, is an endogenous specific substrate of mouse vas deferens protein, an aldose reductase-like protein in adrenocortical cells. (4/279)
Mouse vas deferens protein (MVDP) is an aldose reductase-like protein that is highly expressed in the vas deferens and adrenal glands and whose physiological functions were unknown. We hereby describe the enzymatic characteristics of MVDP and its role in murine adrenocortical Y1 cells. The murine aldose reductase (AR) and MVDP cDNAs were expressed in bacteria to obtain recombinant proteins and to compare their enzymatic activities. Recombinant MVDP was functional and displayed kinetic properties distinct from those of murine AR toward various substrates, a preference for NADH, and insensitivity to AR inhibitors. For MVDP, isocaproaldehyde, a product of side-chain cleavage of cholesterol generated during steroidogenesis, is the best natural substrate identified so far. In Y1 cells, we found that NADH-linked isocaproaldehyde reductase (ICR) activity was much higher than NADPH-linked ICR activity and was not abolished by AR inhibitors. We demonstrate that in Y1 cells, forskolin-induced MVDP expression enhanced NADH-linked ICR activity by 5-6-fold, whereas no variation in ICR-linked NADPH activity was observed in the same experiment. In cells stably transfected with MVDP antisense cDNA, NADH-linked ICR activity was abolished even in the presence of forskolin, and the isocaproaldehyde toxicity was increased compared with that of intact Y1 cells, as measured by isocaproaldehyde LD(50). In Y1 cells transfected with MVDP antisense cDNA, forskolin-induced toxicity was abolished by aminoglutethimide. These results indicate that in adrenocortical cells, MVDP is responsible for detoxifying isocaproaldehyde generated by steroidogenesis. (+info)'Microsmatic' primates revisited: olfactory sensitivity in the squirrel monkey. (5/279)
Using a conditioning paradigm, the olfactory sensitivity of three squirrel monkeys to nine odorants representing different chemical classes as well as members of a homologous series of substances was investigated. The animals significantly discriminated dilutions as low as 1:10,000 n-propionic acid, 1:30,000 n-butanoic acid and n-pentanoic acid, 1:100,000 n-hexanoic acid, 1:1Mio n-heptanoic acid, 1:30, 000 1-pentanol, 1:300,000 1,8-cineole, 1:1Mio n-heptanal and 1:30Mio amyl acetate from the near-odorless solvent, with single individuals scoring even slightly better. The results showed (i) the squirrel monkey to have an unexpectedly high olfactory sensitivity, which for some substances matches or even is better than that of species such as the rat or the dog, and (ii) a significant negative correlation between perceptibility in terms of olfactory detection thresholds and carbon chain length of carboxylic acids. These findings support the assumptions that olfaction may play a significant and hitherto underestimated role in the regulation of primate behavior, and that the concept of primates as primarily visual and 'microsmatic' animals needs to be revised. (+info)Tricaproin, tricaprin and trilaurin are utilized more efficiently than tricaprylin by carp (Cyprinus carpio L.) larvae. (6/279)
We investigated the effect of chain length of dietary medium-chain fatty acids (MCFA) on growth performance and fatty acid composition of first-feeding carp larvae. In a first trial, five semi-purified isolipidic (23-24 g/100 g of dry matter) diets were formulated to contain either 10 g/100 g triolein (control diet) or 5 g/100 g triolein and 5 g/100 g medium-chain triacylglycerols (MCT) supplied as tricaproin, tricaprylin, tricaprin or trilaurin. After 21 d, survival and growth rates were significantly greater in larvae fed diets containing triolein, tricaproin, tricaprin and trilaurin (final survival: 92 +/- 7% and mean larval weight: 42 +/- 15 mg) than in larvae fed tricaprylin (final survival: 56 +/- 12% and mean larval weight: 15 +/- 1 mg). The recovered levels of the fed MCFA in larval total lipids were respectively 0, 1.3, 7.3 and 8.1 g/100 g of total fatty acids. In a second trial, two isolipidic (18 g/100 g) diets containing 10 g/100 g triolein or tricaprylin were tested. High amounts of capric acid (up to 25 g/100 g of total fatty acids) were found in neutral lipids of carp larvae fed tricaprylin for 11 d, suggesting an unusual elongation of caprylic acid. This study underlines the peculiarity of tricaprylin among other MCT which seem well utilized up to 20-30 g/100 g of total dietary fatty acids. The exception of tricaprylin raises the question of the metabolic pathways followed by this MCT, especially for the suggested direct elongation of caprylic acid into capric acid. (+info)Kinetic and stereochemical studies on novel inactivators of C-terminal amidation. (7/279)
C-terminal amidation, a required post-translational modification for the bioactivation of many neuropeptides, entails sequential enzymic action by peptidylglycine alpha-mono-oxygenase (PAM, EC 1.14.17.3) and peptidylamidoglycolate lyase (PGL, EC 4.3.2.5). Here we introduce novel compounds in which an olefinic functionality is incorporated into peptide analogues as the most potent turnover-dependent inactivators of PAM. Kinetic parameters for PAM inactivation by 4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid were obtained by using both the conventional dilution assay method and the more complex progress curve method. The results obtained from the progress curve method establish that these compounds exhibit the kinetic characteristics of pure competitive inactivators (i.e. no ESI complex forms during inactivation). On the basis of k(inact)/K(i) values, 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid is almost two orders of magnitude more potent than benzoylacrylate, a chemically analogous olefinic inactivator that lacks the peptide moiety. Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors. In contrast, 2, 4-dioxo-5-acetamido-6-phenylhexanoic acid, which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and dopamine-beta-hydroxylase. (+info)Hypoxic pulmonary vasoconstriction is modified by P-450 metabolites. (8/279)
20-Hydroxyeicosatetraenoic acid (20-HETE) is a cytochrome P-450 4A (CYP4A) metabolite of arachidonic acid (AA) in human and rabbit lung microsomes and is a dilator of isolated human pulmonary arteries (PA). However, little is known regarding the contribution of P-450 metabolites to pulmonary vascular tone. We examined 1) the effect of two mechanistically distinct omega- and omega1-hydroxylase inhibitors on perfusion pressures in isolated rabbit lungs ventilated with normoxic or hypoxic gases, 2) changes in rabbit PA ring tone elicited by 20-HETE or omega- and omega1-hydroxylase inhibitors, and 3) expression of CYP4A protein in lung tissue. A modest increase in perfusion pressure (55 +/- 11% above normoxic conditions) was observed in isolated perfused lungs during ventilation with hypoxic gas (FI(O(2)) = 0.05). Inhibitors of 20-HETE synthesis, 17-oxydecanoic acid (17-ODYA) or N-methylsulfonyl-12,12-dibromododec-11-enamide (DDMS), increased baseline perfusion pressure above that of vehicle and amplified hypoxia-induced increases in perfusion pressures by 92 +/- 11% and 105 +/- 11% over baseline pressures, respectively. 20-HETE relaxed phenylephrine (PE)-constricted PA rings. Treatment with 17-ODYA enhanced PE-induced contraction of PA rings, consistent with inhibition of a product that promotes arterial relaxation, whereas 6-(20-propargyloxyphenyl)hexanoic acid (PPOH), an epoxygenase inhibitor, blunted contraction to PE. Conversion of AA into 20-HETE was blocked by 17-ODYA, DDMS, and hypoxia. CYP4A immunospecific protein confirms expression of CYP4A in male rabbit lung tissue. Our data suggest that endogenously produced 20-HETE could modify rabbit pulmonary vascular tone, particularly under hypoxic conditions. (+info)Caproates are a type of fatty acid found in breast milk that may have potential health benefits for infants.
I'm sorry, but I couldn't find any information on a medical term called "Caproates." It's possible that you may have misspelled the term or that it is not a commonly used term in the medical field. If you have any additional information or context, please let me know and I'll do my best to assist you.
Gestonorone caproate
... medroxyprogesterone caproate, megestrol caproate, and methenmadinone caproate. Chemical syntheses of gestonorone caproate have ... as well as other caproate progestogen esters such as hydroxyprogesterone caproate. Gestonorone caproate has been found to ... as well as 18-methylsegesterone acetate and the caproate esters chlormadinone caproate, hydroxyprogesterone caproate, ... Cleavage of the caproate ester of gestonorone caproate is minimal, which indicates that it is not a prodrug of the unesterified ...
Chlormadinone caproate
... hydroxyprogesterone caproate, medroxyprogesterone caproate, megestrol caproate, and methenmadinone caproate. List of ... Chlormadinone caproate (CMC) is a progestin and a progestogen ester which was studied for potential use in combined injectable ... In addition to chlormadinone acetate (CMA), analogues of CMC include gestonorone caproate, ... Caproate esters, Chloroarenes, Diketones, Pregnanes, Progestogen esters, Progestogens, All stub articles, Steroid stubs, Genito ...
Nandrolone caproate
... (brand name Anabolin Depot), or nandrolone hexanoate, also known as 19-nortestosterone 17β-hexanoate, is a ... Caproate esters, Nandrolone esters, Progestogens, All stub articles, Genito-urinary system drug stubs, Gastrointestinal system ...
Hydroxyprogesterone caproate
... gestonorone caproate (norhydroxyprogesterone caproate), medroxyprogesterone caproate, megestrol caproate, and methenmadinone ... as well as other caproate progestogen esters such as gestonorone caproate. Hydroxyprogesterone caproate is a much more potent ... Gestonorone caproate, a closely related progestin to hydroxyprogesterone caproate with about 5- to 10-fold greater potency in ... The caproate ester of hydroxyprogesterone caproate is not cleaved during metabolism, so 17α-hydroxyprogesterone is not formed ...
Methenmadinone caproate
... gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone caproate, and megestrol caproate. Estradiol valerate/ ... Methenmadinone caproate (MMC, also known as superlutin caproate) is a progestin medication which was developed in ... methenmadinone caproate List of progestogen esters § Esters of 17α-hydroxyprogesterone derivatives Syhora K, Mazáč R (1964). " ... Caproate esters, Diketones, Pregnanes, Progestogen esters, Progestogens, All stub articles, Steroid stubs, Genito-urinary ...
Testosterone caproate
... (TCa), also known as testosterone hexanoate, is an androgen and anabolic steroid and a testosterone ester ... caproate Testosterone propionate/testosterone phenylpropionate/testosterone isocaproate/testosterone caproate Elks J (14 ... Caproate esters, Testosterone esters, All stub articles, Genito-urinary system drug stubs, Steroid stubs). ...
Megestrol caproate
... gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone caproate, and methenmadinone caproate. Pirzada OL (June ... Megestrol caproate, also known as megestrol 17α-caproate, as well as 17α-hydroxy-6-dehydro-6-methylprogesterone 17α-caproate or ... Megestrol caproate, abbreviated as MGC, is a progestin medication which was never marketed. It was developed in Russia in 2002 ... It is the C17α caproate (hexanoate) ester of megestrol. Closely related medications include megestrol acetate (MGA; megestrol ...
Clostebol caproate
... (brand name Macrobin-Depot), also known as clostebol hexanoate or chlorotestosterone caproate (JAN), as well ... It is an androgen ester - specifically, the C17β caproate ester of clostebol (4-chlorotestosterone) - and acts as a prodrug of ... as 4-chlorotestosterone 17β-caproate or as 4-chloroandrost-4-en-17β-ol-3-one 17β-caproate, is a synthetic, injected anabolic- ... Caproate esters, Organochlorides, Prodrugs, All stub articles, Steroid stubs, Genito-urinary system drug stubs). ...
Medroxyprogesterone caproate
In addition to MPA and OHPC, analogues of MPC include chlormadinone caproate, gestonorone caproate, megestrol caproate, and ... Medroxyprogesterone caproate (MPC) is a progestin and a progestogen ester which was synthesized in 1958 but was never marketed ... McKinnon AO, Tarrida Del Marmol Figueroa S, Nobelius AM, Hyland JH, Vasey JR (1993). "Failure of medroxyprogesterone caproate ... It has been confused with hydroxyprogesterone caproate (OHPC) and medroxyprogesterone acetate (MPA) in a number of publications ...
Gestonorone acetate
Gestonorone caproate Noguchi S (1961). "Steroids. XX. Hydrolysis of steroidal esters by malt enzyme. 1. Selective hydrolysis of ...
Quingestrone
The optimal results are obtained with I caproate. It permits the administration of depot doses in clear solns. Within the range ... Similarly to progesterone, dydrogesterone, and hydroxyprogesterone caproate, quingestrone is a pure progestogen and lacks any ... of progesterone are less suited for use via depot injection relative to progestogen esters like hydroxyprogesterone caproate ...
Progesterone 3-acetyl enol ether
The optimal results are obtained with I caproate. It permits the administration of depot doses in clear solns. Within the range ... It was reported to possess similar potency to progesterone and hydroxyprogesterone caproate in the rabbit endometrial carbonic ... of progesterone are less suited for use via depot injection relative to progestogen esters like hydroxyprogesterone caproate ...
Caproic acid
Several progestin medications are caproate esters, such as hydroxyprogesterone caproate and gestonorone caproate. Two other ... Salts and esters of caproic acid are known as caproates or hexanoates. ...
Estradiol dipropionate
It is also marketed for use in veterinary medicine in combination with hydroxyprogesterone caproate and nandrolone decanoate ... Estradiol dipropionate/hydroxyprogesterone caproate Düsterberg B, Nishino Y (December 1982). "Pharmacokinetic and ... in combination with hydroxyprogesterone caproate), Estroici, Estronex, Follicyclin, Follicyclin P, Follikelmon Depot, Horiken- ... dipropionate remains available at a concentration of 1 mg/mL in combination with 50 mg/mL hydroxyprogesterone caproate under ...
Megestrol acetate
17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce ... Close analogues of MGA that were never marketed include cymegesolate (megestrol acetate 3β-cypionate) and megestrol caproate. ... Pirzada OL (June 2002). "Effect of megestrol caproate on the reproductive function of laboratory animals". Bulletin of ... following hydroxyprogesterone caproate in 1954 and medroxyprogesterone acetate in 1957. The medication was introduced for ...
List of progestogen esters
Hydroxyprogesterone heptanoate benzilic acid hydrazone Medroxyprogesterone caproate Megestrol caproate Methenmadinone caproate ... Esters of 17α-hydroxyprogesterone and 19-norprogesterone derivatives like hydroxyprogesterone caproate, medroxyprogesterone ... Bromethenmadinone acetate Butagest (buterol) Chlormadinone caproate Cismadinone acetate Clogestone acetate (chlormadinol ... Hydroxyprogesterone caproate (Proluton, Proluton Depot, Makena; Delalutin) Medroxyprogesterone acetate (Depo-Provera, Provera) ...
Fluocortolone
"Comparison of betamethasone 17-valerate ointment with fluocortolone and fluocortolone caproate ointment". British Medical ...
Hydroxyprogesterone acetate
Hydroxyprogesterone cap- roate appears to be even less active than Prodox in some respects. It is about 5 times progesterone as ... 17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce ... Junkmann (1954) reported that the acetate, butyrate, and caproate forms had both increased and prolonged activity, [...] Kirk ... hydroxyprogesterone-17-n-caproate, first reported by Karl Junkmann in 1954.6,7 Dorfman RI (1966). Methods in Hormone Research. ...
Progestogen ester
For instance, esters of 17α-hydroxyprogesterone derivatives, such as hydroxyprogesterone caproate, medroxyprogesterone acetate ... 17-alpha hydroxyprogesterone caproate, and related progestins". Am. J. Obstet. Gynecol. 197 (6): 599.e1-7. doi:10.1016/j.ajog. ... and hydroxyprogesterone caproate, the 19-norprogesterone derivative nomegestrol acetate, and the 19-nortestosterone derivatives ... they included 17α-hydroxyprogesterone caproate (Delalutin, Proluton) and 17α-hydroxyprogesterone acetate (Prodrox). The ...
Progestogen (medication)
Other progestogens such as medroxyprogesterone acetate, hydroxyprogesterone caproate, and gestonorone caproate have also been ... Subsequently, high-dose gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate ... 17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce ... Conversely, hydroxyprogesterone caproate possesses no such activity, while progesterone itself has very weak glucocorticoid ...
Hydroxyprogesterone heptanoate
Its potency in animals likewise appears to be similar to that of hydroxyprogesterone caproate. OHPH shows a pronounced depot ... In terms of chemical structure, OHPH is very similar to hydroxyprogesterone caproate, differing from it only in having one ... It appears to have similar pharmacology to that of the closely related medication hydroxyprogesterone caproate (OHPC). OHPH was ... It was also used in Triormon Depositum (estradiol dibutyrate, testosterone caproate, and OHPH) and Trioestrine Retard ( ...
Norethisterone enanthate
17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce ... It was the second long-acting progestogen to be used clinically, after hydroxyprogesterone caproate. The medication was the ...
Feminizing hormone therapy
Some progestins, such as medroxyprogesterone acetate and hydroxyprogesterone caproate, are or can be used by intramuscular or ... Progestogens, such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and other progestins, were also sometimes ... other progestogens that have been reported to have been used in transgender women include hydroxyprogesterone caproate, ...
Clostebol acetate
Clostebol caproate Clostebol propionate Norclostebol Norclostebol acetate Oxabolone Oxabolone cipionate Elks J (14 November ...
Lynestrenol phenylpropionate
17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce ...
Dydrogesterone
17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce ...
Pharmacodynamics of progesterone
17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce ... 17-alpha hydroxyprogesterone caproate, and related progestins". Am. J. Obstet. Gynecol. 197 (6): 599.e1-7. doi:10.1016/j.ajog. ...
Levonorgestrel butanoate
17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce ...
Testosterone butyrate
Testosterone acetate Testosterone caproate Testosterone enanthate Yalkowsky SH, He Y, Jain P (19 April 2016). Handbook of ...
Oxogestone phenpropionate
17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce ...
Makena (hydroxyprogesterone caproate) dosing, indications, interactions, adverse effects, and more
... hydroxyprogesterone caproate), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & ... encoded search term (hydroxyprogesterone caproate (Makena)) and hydroxyprogesterone caproate (Makena) What to Read Next on ... hydroxyprogesterone caproate intramuscular NO MONOGRAPH AVAILABLE AT THIS TIME USES: Consult your pharmacist. HOW TO USE: ... hydroxyprogesterone caproate will increase the level or effect of cyclosporine by Other (see comment). Use Caution/Monitor. ...
A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins - PubMed
Treatment with 17 alpha-hydroxyprogesterone caproate did not reduce the rate of preterm birth in women with twin gestations. ( ... A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins Dwight J Rouse et al. N Engl J Med. 2007. . ... A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins Dwight J Rouse 1 , Steve N Caritis, Alan M ... 17-alpha-hydroxyprogesterone caproate for maintenance tocolysis: a systematic review and metaanalysis of randomized trials. ...
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate - PubMed
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate Paul J Meis et al. N Engl J Med. 2003. . ... Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate Paul J Meis 1 , Mark Klebanoff, Elizabeth ... A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. Rouse DJ, Caritis SN, Peaceman AM, Sciscione ... Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. Brancazio LR, Murtha AP, Heine RP. Brancazio ...
HYDROXYPROGESTERONE CAPROATE Products - LIVE IVF
We focus on distributing IVF & Fertility Medications directly to your doorstep. Our mission is to be 100% committed to making the process of IVF convenient and less costly for you.. The healthy birth of a child and the safety of the mother is our top priority. We provide superior customer service in addition to brand-name medications that will arrive at your home within 3-5 business days.. ...
What's New for 2013 MeSH. NLM Technical Bulletin. 2012 Nov-Dec
Makena (hydroxyprogesterone caproate) dosing, indications, interactions, adverse effects, and more
... hydroxyprogesterone caproate), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & ... encoded search term (hydroxyprogesterone caproate (Makena)) and hydroxyprogesterone caproate (Makena) What to Read Next on ... hydroxyprogesterone caproate intramuscular NO MONOGRAPH AVAILABLE AT THIS TIME USES: Consult your pharmacist. HOW TO USE: ... hydroxyprogesterone caproate will increase the level or effect of cyclosporine by Other (see comment). Use Caution/Monitor. ...
Gut Microbiota in Older People: Metabolism and Composition
Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: A randomized controlled trial<...
Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: A randomized controlled trial. Obstetrics ... The lack of benefit of 17 alpha-hydroxyprogesterone caproate was evident regardless of the conception method or whether a ... The lack of benefit of 17 alpha-hydroxyprogesterone caproate was evident regardless of the conception method or whether a ... The lack of benefit of 17 alpha-hydroxyprogesterone caproate was evident regardless of the conception method or whether a ...
What's New for 2013 MeSH. NLM Technical Bulletin. 2012 Nov-Dec
17-Hydroxyprogesterone, Urine: Reference Range, Interpretation, Collection and Panels
Metabolomics Profiling before, during, and after the Beijing Olympics: A Panel Study of Within-Individual Differences during...
Commission Notices | United States International Trade Commission
Ethyl hexanoate M060024
British Medical Journal: 4 (5574) | The BMJ
Publication Detail
What treatments are used to prevent preterm labor and birth? | NICHD - Eunice Kennedy Shriver National Institute of Child...
Akorn Inc Product News and Research
| CureHunter
Lexical Tools
17P (Progesterone) - UNC Collaborative for Maternal & Infant Health
Biomarkers Search
17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and ... 1. Racial and ethnic disparities in use of 17-alpha hydroxyprogesterone caproate for prevention of preterm birth.. Yee LM; Liu ... 2. Disparities in 17-Hydroxyprogesterone Caproate Offer and Uptake in Pregnancies at a Risk of Preterm Birth.. Berhie SH; Riley ... 9. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm ...
Betaxolol Hydrochloride|N0000004400
AMAG Pharma to Lay Off 140 Staffers as Part of Company Restructure | BioSpace
Mission Possible: Reducing Disparities in Preterm Births in the United States | Blogs | CDC
NCL praises AG Barr for crackdown on COVID-19 scammers - National Consumers League
Preterm Labor - Gynecology and Obstetrics - MSD Manual Professional Edition
4. Meis PJ, Klebanoff M, Thom E, et al: Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N ... hydroxyprogesterone caproate (17-OHPC; 4 Treatment references Labor (contractions resulting in cervical change) that begins ... Use of 17-alpha hydroxyprogesterone caproate for prevention of recurrent preterm birth. Accessed 4/23/21. ... ACOG statement on FDA proposal to withdraw 17p hydroxyprogesterone caproate. 2020. Accessed 7/3/21. ...
Drugs, Biologics, and Regenerative Medicine in 2019: A Successful Year Ends with Promise of a More Challenging 2020 | Mintz
Hydroxyprogesterone Caproate Injection5
- Hydroxyprogesterone caproate injection is used to prevent premature labor in pregnant women in order to reduce the risk of giving birth too early (preterm birth). (moruflifesciences.com)
- Hydroxyprogesterone caproate injection is administered only by or under the supervision of a doctor. (moruflifesciences.com)
- Like other drugs, this Hydroxyprogesterone caproate injection also shows interactions with many other medications which are used to treat other health issues, and these drugs include anti-epilepsy, painkillers, antidiabetics, HIV drugs, and anti-fungal medications. (moruflifesciences.com)
- There are names f certain medications that can be harmful if used with Hydroxyprogesterone caproate injection. (moruflifesciences.com)
- Before applying this Hydroxyprogesterone caproate injection the doctor or professional nurse should read the label information or instructions of the doctor for use. (moruflifesciences.com)
Makena1
- The progesterone shot (sometimes called "17P" for the drug name [17 alpha-hydroxyprogesterone caproate] or its brand name, Makena) can help prevent an early birth. (kidshealth.org)
Alpha-hydroxyprogesterone caproate1
- Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. (medscape.com)
Injection1
- Hydroxyprogesterone Caproate IP 500mg For Injection will be given to you under the skin as an Powder For Injection in a hospital or clinic by a doctor or nurse. (sterisonline.com)
Allyl Caproate1
- Ashapura Aromas Pvt Ltd offers wide range of flavors which includes Allyl Caproate. (ingredientsnetwork.com)
Hydroxyprogesterone caproate injection1
- The company reported total revenues for the quarter of $68.7 million, including $44.4 million from the sales of Feraheme and $21.8 million from Makena (hydroxyprogesterone caproate injection). (biospace.com)
Preterm7
- 2. Disparities in 17-Hydroxyprogesterone Caproate Offer and Uptake in Pregnancies at a Risk of Preterm Birth. (nih.gov)
- 3. Spontaneous preterm birth in African-American and Caucasian women receiving 17α-hydroxyprogesterone caproate. (nih.gov)
- 8. Factors Associated with Utilization of 17-Hydroxyprogesterone Caproate for the Prevention of Recurrent Preterm Birth. (nih.gov)
- 9. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth. (nih.gov)
- 10. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth. (nih.gov)
- 15. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps. (nih.gov)
- One of the drugs AMAG is holding onto is Makenda, a weekly injection of hydroxyprogesterone caproate designed to decrease the risk of preterm birth for pregnant women with a history of spontaneous preterm birth. (biospace.com)
Women1
- 11. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study. (nih.gov)